Conveners
Session 1 - Radiopharmaceutical Chemistry (radiodiagnostics, radiotherapy, theragnostics)
- Cathy Cutler (University of Missouri, USA)
-
Prof. Jean-François chatal (GIP ARRONAX, France)17/09/2012, 10:00Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureFor the last two decades a technological revolution has deeply changed the field of application of nuclear medicine. Today PET/CT imaging using 18F-Fluorodeoxyglucose (FDG) is considered as the standard imaging technique in oncology for tumor staging, detection of recurrence and early evaluation of response to treatment. PET/MRI could shortly become the standard imaging technique in neurology....Go to contribution page
-
Prof. Suresh Srivastava (Brookhaven National Laboratory, USA)17/09/2012, 10:30Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureA major advantage of radionuclides is that they emit radiation of different radiobiological effectiveness and range of action. This offers the possibility of choosing a nuclide the physical and nuclear characteristics of which are matched with a particular tumor type, or the disease under treatment. This presentation introduces a relatively novel paradigm that involves specific individual...Go to contribution page
-
Prof. Roger Alberto (University of Zurich, Switzerland)17/09/2012, 11:00Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureImaging and visualization of molecular events on the cellular and subcellular level requires the design and the syntheses of highly specific compounds which have to to accumulate at desired target sites but should be rapidly cleared from non-targeted organs. Visualization must take place at the living intact subject and the patient.[1] This makes radiolabeled compounds a priority modality for...Go to contribution page
-
Prof. Frank Roesch (University of Mainz, Germany)17/09/2012, 11:20Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureIntroduction: Radionuclide generator systems continue to play a key role in providing both diagnostic and therapeutic radionuclides for various applications in nuclear medicine, oncology and interventional cardiology. In parallel to the well established 99Mo/99mTc generator used for SPECT imaging, new generators for PET/CT imaging attract attention. In particular the...Go to contribution page
-
Dr Marco Chinol (European Institute of Oncology, Italy), Dr Stefano Papi (European Institute of Oncology, Italy)17/09/2012, 11:40Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureSomatostatin analogues designed to target tumor cells over-expressing somatostatin receptors have been radiolabelled with 90Y- and 177Lu for peptide receptor radionuclide therapy (PRRT). Clinical trials evidenced large patient variability as regards tumor and organs uptake, thus sustaining the need of tailored dosimetry, for a treatment course with improved safety and efficacy. However,...Go to contribution page
-
Dr Stanislav Pavelka (Department of Radiometry, Institute of Physiology, v.v.i., Academy of Sciences of the Czech Republic, Prague; and Institute of Biochemistry, Masaryk University, Brno, Czech Republic)17/09/2012, 12:00Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral CommunicationsPavelka S.1,2, Macek Jílková Z.3 and Kopecký J.3 1Department of Radiometry, Institute of Physiology, v.v.i., Academy of Sciences of the Czech Republic, Prague; 2Institute of Biochemistry, Masaryk University, Brno; and 3Department of Adipose Tissue Biology, Institute of Physiology, v.v.i., ASCR, Prague, Czech Republic The metabolism of thyroid hormones (TH) in white adipose tissue (WAT)...Go to contribution page
-
Dr Sandrine Huclier-Markai (Laboratoire Subatech, UMR 6457, Ecole des Mines de Nantes /CNRS/IN2P3 / Université de Nantes, 4 Rue A. Kastler, BP 20722, F-44307 Nantes Cedex 3, France.)17/09/2012, 12:15Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral CommunicationsThe use of radionuclides as potential therapeutic radiopharmaceuticals is increasingly investigated. Scandium isotopes (44Sc, 47Sc) become more easily available and their properties are convenient for either PET imaging or radiotherapy. Notably, the half-life of 3.97 h of 44Sc and its high positron branching (94%) lead us to consider this isotope for application in TEP radiopharmaceuticals....Go to contribution page
-
Mr Seweryn Krajewski (Institute of Nuclear Chemistry and Technology, Dorodna Street 16, 01312 Warsaw, Poland)17/09/2012, 12:30Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral CommunicationsRecently, great effort is put in development of personalised treatment, including precise diagnoses and therapy using the same molecular targeting vectors. Scandium radioisotopes give opportunity to obtain PET/CT images using 44Sc (τ1/2 = 3.92 h) and 43Sc (τ1/2 = 3.89 h) and to treat tumours with a low energy β--particles using 47Sc (τ1/2 = 3.35 d). The aim of our work was to developed simple...Go to contribution page
-
Ms Edyta Leszczuk (Institute of Nuclear Chemistry and Technology, Poland)17/09/2012, 12:45Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral CommunicationsThere are only a few a-particle emitting radionuclides that have properties suitable for developing therapeutic radiopharmaceuticals. Unfortunately, all available a-emitters have serious disadvantages: 211At forms weak bond with carbon atoms in the biomolecule and in the case of 212Bi, 213Bi and 226Th short half-life often limits the application of these nuclides. However, the short half-life...Go to contribution page